Allergic Rhinitis Due to House Dust Mite Clinical Trial
Official title:
A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma worsening.
The trial aims to demonstrate efficacy of the HDM SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with HDM allergic asthma based on clinically relevant asthma exacerbations. Additionally, the trial will investigate if the treatment has an effect on asthma symptoms including nightly awakenings due to asthma, asthma medication use, asthma control, lung function, allergic rhinitis and allergic rhinoconjunctivitis. Finally, quality of life (QoL) for subjects and caregivers will be measured. The trial is a randomised, parallel-group, double-blind, placebo-controlled multi-national phase III trial conducted in Europe and North America. The treatment period will be approximately 2 years. Subjects will receive a written asthma action plan. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04145219 -
House Dust Mite Allergy Trial In Children
|
Phase 3 | |
| Not yet recruiting |
NCT05510024 -
Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial
|
N/A | |
| Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|
||
| Completed |
NCT03746860 -
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
|
||
| Enrolling by invitation |
NCT05960526 -
Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis
|
Phase 1 | |
| Active, not recruiting |
NCT04286542 -
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
|
N/A |